A country may offer world-class fertility treatment but still be unable to help the patient who needs it most. Across borders, IVF access depends on a complicated mix of national laws, family status and rules governing donor eggs, sperm and surrogacy.
A married couple in Istanbul learns that they need donor eggs to have a child. Their doctor explains that the treatment isn’t legally available in Turkey. They begin looking abroad, weighing clinics in Greece, Spain and other countries where donor treatment is permitted.
The couple faces a difficult decision. They must consider medical costs, travel arrangements and the emotional strain of treatment. They also need to understand a legal system that may differ sharply from the one they know at home.
This is the challenge at the heart of cross-border fertility care.
For patients who cannot access a particular treatment in their home country, traveling abroad can open new possibilities. But crossing a border doesn’t automatically resolve the legal or medical risks.
The destination country must permit the specific treatment, accept the patient under its eligibility rules and provide a clear legal framework for the resulting family arrangements.
Medical Tourism Watch’s fertility-law database examines these differences across 23 jurisdictions, covering donor treatment, donor anonymity, surrogacy and access for single women and same-sex couples. The findings reveal a fragmented market in which the same treatment can be available to one patient but prohibited for another.
The following analysis draws on the database and selected official legal sources. Because reproductive laws and administrative practices change, the information should be verified before publication and updated regularly.
Europe: Similar healthcare systems, different rules
Europe has become a major destination for international fertility patients. Yet there is no common European approach to assisted reproduction.
Countries differ on who can receive treatment, whether donor identities can eventually be disclosed and whether surrogacy is permitted.
Spain illustrates how a country can combine broad access to donor treatment with strict rules on donor identity.
Under Spain’s established assisted-reproduction framework, egg, sperm and embryo donation are permitted, while donor anonymity is generally required. Single women and same-sex couples can access assisted reproduction under applicable rules.
For patients who want donor treatment but prefer an anonymous system, Spain may be an option. For those who want their future child to have a legal route to identifying the donor, the rules present a different set of considerations.
Portugal took a different direction.
Following a 2018 Constitutional Court decision, Portugal moved toward a system that allows donor-conceived people to obtain identifying information about their donors when they reach adulthood.
That change has implications for both patients and children born through donation. It also demonstrates how a court decision can reshape the practical choices available in the fertility market.
Donor anonymity isn’t simply a clinic policy. In many countries, it’s a matter of law.
Patients should ask clinics what donor information is collected, who can access it and what rights a donor-conceived child may have in the future.
Greece offers a distinct legal route for surrogacy
Greece occupies a different position within Europe’s fertility market.
Egg, sperm and embryo donation are permitted, and the framework allows access to treatment for single women. Female same-sex couples may also have access under applicable rules.
Greece also permits gestational surrogacy under specific conditions, including prior judicial approval.
That approval is a central part of the process. Intended parents cannot assume that finding a willing clinic means they are legally authorized to proceed.
For international patients considering surrogacy, the legal process can affect treatment timing, expenses and the arrangements required before a child is born.
The European Union itself doesn’t establish a single set of surrogacy rules. Each member state determines its own approach, and national policies continue to evolve.
Legal donation doesn’t always mean unrestricted access
The Czech Republic and Poland illustrate another important distinction.
Both countries have frameworks that permit certain forms of donor-assisted reproduction. But eligibility restrictions can limit access for single women and same-sex couples.
This creates a situation in which a clinic may offer donor treatment while still being unable to accept a particular patient.
For international visitors, the relevant question isn’t simply whether a country permits IVF.
It is whether the specific patient, treatment and family circumstances meet the country’s legal requirements.
Turkey: When donor treatment isn’t an option
Turkey provides a clear example of how domestic restrictions can influence international fertility travel.
Under Turkish law, assisted reproduction is restricted to married couples using their own reproductive material. The use of another person’s reproductive cells or embryos is prohibited.
Egg donation, sperm donation and embryo donation are therefore not available through the country’s legally authorized fertility system.
The restrictions are set out in Turkish legislation governing assisted reproductive treatment.
For a Turkish couple who needs donor eggs, treatment abroad may become a consideration.
But traveling to another country doesn’t change the rules that apply to treatment in Turkey. Patients must also understand the legal requirements governing the use of donor material and any resulting family arrangements in their home country.
Turkey’s experience highlights a broader point: the availability of fertility treatment at home and the availability of treatment abroad are increasingly connected.
When a country restricts donor treatment, patients may look elsewhere. The resulting demand can influence referral networks and the international patient strategies of fertility clinics.
The existence of such demand, though, doesn’t guarantee that every overseas treatment arrangement is lawful or medically appropriate.
Georgia: The risks of regulatory uncertainty
Georgia has been associated with international surrogacy, particularly for married heterosexual foreign couples.
The country’s rules and the government’s proposed changes have made it a difficult market for patients to assess.
The fertility database records a proposed restriction on foreign surrogacy announced in 2023, with subsequent uncertainty over implementation.
This distinction matters. A government announcement is not necessarily the same as an enforceable law.
At the same time, a delayed legislative change should not be treated as a guarantee that existing arrangements will remain available.
For patients who are already undergoing treatment, uncertainty can create serious practical problems. They may have embryos stored at a clinic, contracts with service providers and travel arrangements that depend on the existing legal framework.
A change in the law could affect the ability to complete treatment or establish legal parentage.
Patients considering Georgia should obtain current advice from qualified local legal professionals before entering into an arrangement.
They should also ask how a clinic will handle changes in the law during an ongoing treatment cycle.
India: A major shift in the surrogacy market
India was once a prominent destination for international surrogacy.
Its regulatory framework has since changed significantly.
The Surrogacy (Regulation) Act, 2021 prohibits commercial surrogacy and establishes restrictions on who can participate in surrogacy arrangements.
India’s official guidance also confirms that foreign nationals cannot simply travel to the country to commission surrogacy. Restrictions on visas and related permissions have applied to foreign intended parents.
The Assisted Reproductive Technology (Regulation) Act, 2021 introduced a separate framework for fertility clinics and reproductive technology banks.
Together, these laws have reshaped the conditions under which fertility services can be provided.
For international patients, the lesson is straightforward: a country’s history as a fertility destination doesn’t establish that the same services remain available today.
Patients should rely on current legislation and official guidance rather than older clinic advertisements or travel articles.
Latin America: Access and legal certainty aren’t the same thing
Several Latin American countries appear in the fertility database as destinations where donor treatment is available and access is broader for single women and same-sex couples.
But the legal treatment of surrogacy varies considerably.
Mexico: Rules can differ by state
Mexico permits assisted reproductive services, including donor treatment.
Surrogacy, however, has developed unevenly across the country. State-level differences and legal developments following a 2021 Supreme Court decision mean that patients need to examine the rules in the specific state where treatment is planned.
A legal arrangement that may be possible in one location cannot automatically be assumed to be available elsewhere in Mexico.
Patients should also determine how the relevant authorities handle parentage and birth registration.
Colombia: Court decisions shape the framework
Colombia permits assisted reproductive treatment, and the database identifies access for single women and same-sex couples.
Surrogacy, by contrast, has developed without a comprehensive, dedicated statutory framework.
Court decisions and legal interpretations have influenced how arrangements are assessed.
For international patients, this can create uncertainty. The absence of a single, detailed surrogacy law makes it especially important to obtain case-specific legal advice before treatment.
Argentina: Broad access, but questions remain
Argentina’s Law 26.862 provides a legal framework for assisted reproduction.
The country permits donor treatment and offers access to a broad range of patients under its applicable rules.
Surrogacy is not governed by a dedicated, comprehensive statute. Legal questions surrounding parentage may therefore require particular attention.
Patients considering treatment in Argentina should distinguish between access to IVF and the legal arrangements associated with surrogacy.
These examples show why describing a country as a “fertility-friendly destination” can be misleading.
A country may offer broad access to IVF while leaving important questions about surrogacy or parentage unresolved.
Donor anonymity: A decision with lifelong implications
For many patients, donor anonymity is a central consideration.
Some families prefer a system that protects the donor’s identity. Others believe children conceived through donation should have the opportunity to learn about their genetic origins.
Different countries have adopted different approaches.
| Country | Donor treatment | Donor identity rules |
|---|---|---|
| Spain | Egg, sperm and embryo donation permitted under applicable rules | Donor anonymity generally required |
| Portugal | Donor treatment permitted | Open-identity framework following legal changes |
| Greece | Egg, sperm and embryo donation permitted | Anonymous and non-anonymous options under applicable rules |
| Denmark | Donor treatment permitted | Anonymous and open-identity options available |
| Turkey | Third-party donation prohibited | Not applicable to legally permitted domestic treatment |
This summary reflects the supplied database and selected legal sources. It is not a substitute for current country-specific legal advice.
The issue extends beyond the treatment itself.
A child born through donation may live in a different country from the one where the treatment took place. The rules governing access to donor information may therefore have consequences long after the clinic visit.
Patients should ask whether donor information will remain available if they move abroad, whether identifying information can be accessed in adulthood and how the clinic handles changes in national law.
These questions deserve attention before treatment begins.
Who can access treatment?
Eligibility is another major dividing line in international fertility care.
Some countries permit treatment for single women and same-sex couples. Others limit access to married heterosexual couples or require the use of the couple’s own reproductive material.
The differences can have direct consequences for patients seeking care abroad.
A single woman may be eligible for donor IVF in Spain or Portugal but face restrictions in another European country.
A same-sex couple may find that a clinic offers fertility services but cannot legally provide the treatment they require.
A married couple seeking donor eggs may find that their home country prohibits third-party donation altogether.
These distinctions should be assessed before a patient pays a deposit or begins medication.
A clinic’s marketing materials may describe its services broadly. That description doesn’t necessarily establish that every advertised treatment is available to every international patient.
What patients should check before traveling
Cross-border fertility treatment involves more than choosing a clinic and booking a flight.
Patients should establish whether their proposed treatment is legal and whether the resulting family arrangements will be recognized after they return home.
Before making a decision, they should seek clear answers to the following questions:
Is my treatment permitted?
Does the destination country allow the specific procedure I need, including donor eggs, donor sperm, embryo donation or surrogacy?
Am I eligible?
Do the country’s rules cover my marital status, nationality, age and family structure?
What do I know about the donor?
Can I access non-identifying medical information? Will my future child have a legal right to obtain identifying information?
What happens if the law changes?
Are there safeguards for patients who have already started treatment or have embryos stored at a clinic?
Will my home country recognize the outcome?
If surrogacy is involved, who will be recognized as the legal parent after birth? What documents will be required to return home with the child?
Is the clinic properly authorized?
Patients should verify the clinic’s licensing, laboratory standards and the qualifications of the medical team.
Independent legal advice is particularly important when treatment involves donor material, surrogacy or more than one country.
What the changing rules mean for the fertility industry
The international fertility market is shaped by more than medical technology and treatment prices.
Regulation plays a central role.
Countries with established treatment pathways may attract patients who cannot access the same services at home. But legal restrictions can also redirect demand to other destinations.
For clinics, this creates an obligation to communicate accurately.
A fertility provider should make clear which services it can legally offer, which patients it can accept and what limitations may apply to international treatment.
For medical-tourism platforms, the challenge is equally significant.
A directory that lists clinics without explaining relevant legal restrictions may leave patients with an incomplete picture of their options.
Better information can help patients ask more informed questions. It cannot replace professional medical or legal advice, but it can make the process more transparent.
The value of a fertility destination increasingly depends not only on what its clinics can do, but also on how clearly they explain what patients can legally expect.
The map will continue to change
Fertility law reflects a country’s approach to family formation, reproductive rights, donor protection and the interests of children born through assisted reproduction.
Those priorities can change through legislation, court decisions and administrative action.
The result is a market in which yesterday’s treatment destination may not offer the same services tomorrow.
For patients, the safest approach is to examine the law governing their specific circumstances rather than rely on a country’s reputation or a clinic’s promotional material.
For providers and medical-tourism platforms, accurate information is part of patient safety.
Cross-border fertility care will continue to connect patients with treatment options around the world. But access must be assessed one patient, one procedure and one legal system at a time.
Disclaimer: This article is for informational purposes only. It does not constitute medical or legal advice. Fertility laws, eligibility requirements and administrative practices can change. Patients should consult qualified fertility specialists and reproductive-law professionals in both the destination country and their home country before arranging treatment abroad.